These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8797308)

  • 1. [Clinical study of prulifloxacin on infectious enteritis. Japan Research Committee of Prulifloxacin, Research Group on Infectious Enteritis].
    Tomizawa I; Takizawa Y; Nitta Y; Tsunoda T; Fukuda H; Yamaguchi T; Masuda G; Negishi M; Ajisawa A; Murata M; Ohnishi K; Irimajiri S; Obana M; Sajima Y; Sagara H; Kato H; Hosoda S; Banba T; Sasaki M; Yoshikawa K; Nakagawa M; Ohkubo H; Kim Y; Akao M; Fukuyama M
    Kansenshogaku Zasshi; 1996 Jul; 70(7):727-45. PubMed ID: 8797308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical trial of T-3262 on acute enteritis. Japan Research Committee of T-3262, Research Group for Acute Infectious Enteritis].
    Aoki T; Matsubara Y; Sagara H; Tomizawa I; Takizawa Y; Nitta Y; Seo T; Kamimura M; Masuda G; Negishi M
    Kansenshogaku Zasshi; 1989 Jun; 63(6):593-605. PubMed ID: 2693541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical trial of T-3262 (Tosufloxacin tosilate) on Salmonella enteritis, and fecal drug concentration and change in the fecal microflora in the acute diarrheal patients. Japan Research Committee of T-3262, Research Group for Acute Infectious Enteritis].
    Aoki T; Matsubara Y; Sagara H; Shimizu N; Tomizawa I; Takizawa Y; Nitia Y; Seo T; Kamimura M; Kanehisa N
    Kansenshogaku Zasshi; 1989 Jul; 63(7):659-75. PubMed ID: 2693543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro antibacterial activity of pazufloxacin (PZFX) against clinical isolates from infectious enteritis].
    Fukuyama M; Oonaka K; Hara M; Imagawa Y
    Kansenshogaku Zasshi; 1996 Jan; 70(1):51-9. PubMed ID: 8822053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [clinical study of balofloxacin on infectious enteritis and assessment of the fecal drug concentration and intestinal microbial flora in patients with inpatients with infectious enteritis. Research group of balofloxacin on infectious enteritis].
    Obana M; Irimajiri S; Tomizawa I; Takizawa Y; Sakamoto Y; Nitta Y; Tsunoda T; Fukuda H; Yamaguchi T; Masuda G
    Kansenshogaku Zasshi; 1995 Sep; 69(9):991-1006. PubMed ID: 7594801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Basic and clinical studies of pazufloxacin on infectious enteritis research group of T-3761 on infectious enteritis].
    Sagara H; Yoshikawa K; Tomizawa I; Takizawa Y; Nitta Y; Tsunoda T; Fukuda H; Yamaguchi T; Masuda G; Negishi M; Ajisawa A; Murata M; Ohnishi K; Irimajiri S; Obana M; Matsumoto F; Imai T; Sakurai I; Takahashi T; Mori M; Mizuno Y; Katoh K; Hosoda S; Bamba T; Saito M
    Kansenshogaku Zasshi; 1996 Jan; 70(1):60-72. PubMed ID: 8822054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
    Inoue M; Kuga A; Kaieda S; Hosaka M; Kitasato H; Sato Y; Okamoto R; Eda T; Hoshino K; Seto I
    Jpn J Antibiot; 2000 Sep; 53(9):593-608. PubMed ID: 11214999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Basic and clinical studies of fleroxacin on infectious enteritis. Research Group of AM-833 on infectious enteritis].
    Sagara H; Tomizawa I; Takizawa Y; Nitta Y; Tsunoda T; Yamaguchi T; Masuda G; Negishi M; Ajisawa A; Murata M
    Kansenshogaku Zasshi; 1994 Nov; 68(11):1390-408. PubMed ID: 7829908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
    Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
    Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro antibacterial activity of balofloxacin (BLFX) against isolates from patients with bacterial enteritis].
    Fukuyama M; Kawakami K; Suda O; Imagawa Y
    Kansenshogaku Zasshi; 1995 Sep; 69(9):987-90. PubMed ID: 7594800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro antimicrobial activity of DR-3355, a new quinolone antibacterial agent, against clinical isolates of enteritis-causing bacteria].
    Horiuchi S; Inagaki Y; Yamamoto N; Ogawa M; Nakaya R
    Kansenshogaku Zasshi; 1992 Jan; 66(1):51-8. PubMed ID: 1402063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transporter-mediated hepatic uptake of ulifloxacin, an active metabolite of a prodrug-type new quinolone antibiotic prulifloxacin, in rats.
    Yagi Y; Aoki M; Iguchi M; Shibasaki S; Kurosawa T; Kato Y; Tsuji A
    Drug Metab Pharmacokinet; 2007 Oct; 22(5):350-7. PubMed ID: 17965518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Susceptibility surveillance of clinical isolates to fluoroquinolone antimicrobial agents from 2003 to 2008: post-marketing study of prulifloxacin].
    Kawai S; Yoshida A; Okazaki M; Tsujihara Y; Inuzuka K; Takeuchi K; Yamashita N; Onodera M; Hiraishi T; Ida T; Maebashi K
    Jpn J Antibiot; 2010 Jun; 63(3):242-54. PubMed ID: 20976880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
    Araake M; Hara T; Watabe H; Nishino T
    Jpn J Antibiot; 2002 Dec; 55(6):778-90. PubMed ID: 12621732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro antibacterial activity of fleroxacin (FLRX) against clinical isolates from bacterial enteritis].
    Imagawa Y; Fukuyama M; Kawakami K; Suda O
    Kansenshogaku Zasshi; 1994 Nov; 68(11):1409-16. PubMed ID: 7829909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
    Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
    Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of clinical efficacy of lomefloxacin (LFLX, NY-198) and pipemidic acid (PPA) in the treatment of infectious enteritis by a double-blind method. The Japan Research Committee of Lomefloxacin Research Group Enteritis].
    Aoki T; Shimizu N; Tomizawa I; Takizawa Y; Matsubara Y; Nitta Y; Sagara H; Seo T; Kanehisa N; Murata M
    Kansenshogaku Zasshi; 1989 Jun; 63(6):606-22. PubMed ID: 2693542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic characteristics of prulifloxacin.
    Matera MG
    Pulm Pharmacol Ther; 2006; 19 Suppl 1():20-9. PubMed ID: 16360331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A photoallergenicity study of prulifloxacin (NM441) in guinea pigs].
    Kamata K; Ogawa A; Inoue T; Ishihara M; Ishimura K; Sumi N; Asaoka H; Shindo Y
    J Toxicol Sci; 1996 Jun; 21 Suppl 1():259-65. PubMed ID: 8709166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration.
    Okuyama Y; Momota K; Morino A
    Arzneimittelforschung; 1997 Mar; 47(3):276-84. PubMed ID: 9105546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.